Vaccine technology company, Vaxart, names W. Mark Watson as new Independent Chairperson.
Vaxart Appoints W. Mark Watson as Lead Independent Director
Vaxart, a clinical-stage biotechnology company developing oral recombinant vaccines, has announced the appointment of W. Mark Watson as Lead Independent Director. Mr. Watson, a seasoned professional with over 50 years of experience, has served on Vaxart's Board since August 2022.
Vaxart is known for its innovative vaccine delivery platform, which eliminates the risk of needle-stick injury. The company's vaccines are designed to be administered using pills that do not require refrigeration. Vaxart's development programs include pill vaccines for coronavirus, norovirus, influenza, and human papillomavirus (HPV).
Mr. Watson has held numerous board and trustee positions at other biotech companies. He served as a Chairman of the Board of Directors and Chairman of the Audit Committee of Inhibitor Therapeutics, Inc. and as a Director and Chair of the Audit Committee of Sykes Enterprises, Inc. and BioDelivery Sciences International, Inc. He also serves on the Board of Moffitt Cancer Center as its Risk, Audit and Compliance Committee Chair.
In addition to his role at Vaxart, Mr. Watson served as a trustee of Tekla World Healthcare Fund, Tekla Healthcare Opportunities Fund, Tekla Healthcare Investors, and Tekla Life Sciences Investors until the Fall of 2023. Investors and security holders may obtain information about the Company's directors and executive officers from the definitive proxy statement filed with the U.S. Securities and Exchange Commission (SEC).
The management of Vaxart Inc. has proposed a stock ownership policy for its Directors, aiming to better align the interests of directors with those of shareholders. Vaxart has filed broad domestic and international patent applications for its proprietary technology and creations for oral vaccination.
Vaxart's first immune-oncology indication is for HPV. The company believes its platform is suitable for delivering recombinant vaccines and designing new indications.
Vaxart is encouraging all stockholders of record on July 29, 2025, who have not yet voted FOR the reverse stock split, to do so by 11:59 p.m. Eastern Time on September 18, 2025. The special meeting of Vaxart's stockholders will be held on September 19, 2025, in a virtual-only format. For questions or assistance with voting, contact Vaxart's proxy solicitation firm: Campaign Management, LLC (Toll-Free: 1-855-264-1527, Email: [email protected]).
Stockholders are encouraged to review the proxy statement carefully before voting. The definitive proxy statement, along with other important information, will be available at www.proxyvote.com, www.vaxart.com, or by contacting Vaxart's proxy solicitation firm.
Read also:
- chaos unveiled on Clowning Street: week 63's antics from 'Two-Tier Keir' and his chaotic Labour Circus
- Skechers Debuts First American Stores Focused on Athletic Footwear Performance
- Racing ahead in Renewable Energy Dominance: Changzhou, Jiangsu Pushes for Worldwide Renewable Energy Ascendancy
- Unchecked carbon emissions could potentially lead the world to revert to coal usage, according to a knowledgeable source.
